Frederico Nakane Nakano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Frederico Nakane Nakano has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Adélia Maria de Miranda Henriques-Souza
Instituto de Medicina Integral Professor Fernando Figueira, Recife PE, Brazil
1 shared publication - Américo Ceiki Sakamoto
Department of Neurosciences and Behaviour Sciences Universidade de São Paulo, Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto Ribeirão Preto São Paulo Brazil
1 shared publication - André Palmini
Porto Alegre Epilepsy Surgery Program Neurology and Neurosurgery Services, Hospital São Lucas, Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS) Porto Alegre Brazil
1 shared publication - Antonio Carlos Amedeo Vattimo
Medical Department, Aché Pharmaceuticals Laboratories S. A., São Paulo, Brazil
1 shared publication - Antonio Carlos dos Santos
Department of Neurosciences and Behaviour Sciences Universidade de São Paulo, Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto Ribeirão Preto, São Paulo Brazil
1 shared publication - Douglas Costa Morais
Possibilidade de alterá-la de nenhuma forma ou utilizá-la para fins comerciais
1 shared publication
Latest Publications
- Open Access
- 8 October 2026
- Published by Wiley in Epileptic Disorders
Pragmatic screening for autoimmune‐associated epilepsy in drug‐resistant epilepsy of unknown etiology in resource‐limited settings: A hypothesis‐generating study
Objective: To evaluate the feasibility of investigating autoimmune etiology in adults with drug‐resistant epilepsy (DRE) of unknown origin in resource‐limited settings and to develop a pragmatic, hypothesis‐generating screening approach to guide autoantibody testing. Methods: A prospective observational study including adults with DRE of unknown etiology was conducted at a tertiary epilepsy center in Brazil. All patients underwent standardized assessment including inflammatory and autoimmunity markers, brain magnetic resonance imaging (MRI), electroencephalography (EEG), cerebrospinal fluid (CSF) analysis, and application of the APE2 and ACES scores. Clinical, laboratory, and imaging findings were analyzed in the context of published autoimmune‐associated epilepsy (AAE) profiles to inform a pragmatic screening strategy. Results: Twenty‐six patients (46.2% female; median epilepsy duration: 18.5 years) were included. EEG findings were nonspecific. Six patients developed mesial temporal abnormalities on follow‐up MRI. CSF protein elevation was observed in 37.5%, oligoclonal bands in 13.6%, and elevated IgG index in 18.2%. Antinuclear antibodies were detected in 26.9%. APE2 score ≥ 4 was present in 57.7%, while ACES score ≥ 2 occurred in 11.5%. Due to limited access to antibody testing, only one patient underwent CSF autoantibody analysis, confirming high‐titer anti‐GAD65. Based on integrated clinical, laboratory, and imaging findings, a pragmatic screening algorithm was proposed to prioritize candidates for autoantibody testing. Significance: In resource‐limited settings, systematic use of accessible clinical and laboratory markers may help identify patients with higher pre‐test probability of AAE. A pragmatic screening approach may improve diagnostic efficiency and support individualized decision‐making when comprehensive antibody testing is not readily available.
- 8 October 2026
- Published by Wiley in Epileptic Disorders
Open AccessPragmatic screening for autoimmune‐associated epilepsy in drug‐resistant epilepsy of unknown etiology in resource‐limited settings: A hypothesis‐generating study
Objective: To evaluate the feasibility of investigating autoimmune etiology in adults with drug‐resistant epilepsy (DRE) of unknown origin in resource‐limited settings and to develop a pragmatic, hypothesis‐generating screening approach to guide autoantibody testing. Methods: A prospective observational study including adults with DRE of unknown etiology was conducted at a tertiary epilepsy center in Brazil. All patients underwent standardized assessment including inflammatory and autoimmunity markers, brain magnetic resonance imaging (MRI), electroencephalography (EEG), cerebrospinal fluid (CSF) analysis, and application of the APE2 and ACES scores. Clinical, laboratory, and imaging findings were analyzed in the context of published autoimmune‐associated epilepsy (AAE) profiles to inform a pragmatic screening strategy. Results: Twenty‐six patients (46.2% female; median epilepsy duration: 18.5 years) were included. EEG findings were nonspecific. Six patients developed mesial temporal abnormalities on follow‐up MRI. CSF protein elevation was observed in 37.5%, oligoclonal bands in 13.6%, and elevated IgG index in 18.2%. Antinuclear antibodies were detected in 26.9%. APE2 score ≥ 4 was present in 57.7%, while ACES score ≥ 2 occurred in 11.5%. Due to limited access to antibody testing, only one patient underwent CSF autoantibody analysis, confirming high‐titer anti‐GAD65. Based on integrated clinical, laboratory, and imaging findings, a pragmatic screening algorithm was proposed to prioritize candidates for autoantibody testing. Significance: In resource‐limited settings, systematic use of accessible clinical and laboratory markers may help identify patients with higher pre‐test probability of AAE. A pragmatic screening approach may improve diagnostic efficiency and support individualized decision‐making when comprehensive antibody testing is not readily available.
- Open Access
- 1 April 2021
- Published by FapUNIFESP (SciELO) in Arquivos de Neuro-Psiquiatria
- Vol. 79 (4) , 290-298
Efficacy and safety of levetiracetam as adjunctive therapy for refractory focal epilepsy
Background: Epilepsy affects about 50 million people worldwide and around 30% of these patients have refractory epilepsy, with potential consequences regarding quality of life, morbidity and premature mortality. Objective: The aim of treatment with antiseizure medications (ASMs) is to allow patients to remain without seizures, with good tolerability. Levetiracetam is a broad-spectrum ASM with a unique mechanism of action that differs it from other ASMs. It has been shown to be effective and safe for treating adults and children with epilepsy. Methods: This was a phase III, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of levetiracetam in children and adults (4-65 years) as an adjuvant treatment for focal-onset seizures. It was conducted among 114 patients undergoing treatment with up to three ASMs. The primary efficacy analysis was based on the proportion of patients who achieved a reduction of ≥ 50% in the mean number of focal seizures per week, over a 16-week treatment period. The patients were randomized to receive placebo or levetiracetam, titrated every two weeks from 20 mg/kg/day or 1,000 mg/day up to 60 mg/kg/day or 3,000 mg/day. Results: Levetiracetam was significantly superior to placebo (p = 0.0031); 38.7% of the participants in the levetiracetam group and 14.3% in the control group shows reductions in focal seizures. Levetiracetam was seen to have a favorable safety profile and an adverse event rate similar to that of placebo. Conclusion: Corroborating the results in the literature, levetiracetam was shown to be effective and safe for children and adults with refractory focal-onset epilepsy.
- 1 April 2021
- Published by FapUNIFESP (SciELO) in Arquivos de Neuro-Psiquiatria
- Vol. 79 (4) , 290-298
Open AccessEfficacy and safety of levetiracetam as adjunctive therapy for refractory focal epilepsy
Background: Epilepsy affects about 50 million people worldwide and around 30% of these patients have refractory epilepsy, with potential consequences regarding quality of life, morbidity and premature mortality. Objective: The aim of treatment with antiseizure medications (ASMs) is to allow patients to remain without seizures, with good tolerability. Levetiracetam is a broad-spectrum ASM with a unique mechanism of action that differs it from other ASMs. It has been shown to be effective and safe for treating adults and children with epilepsy. Methods: This was a phase III, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of levetiracetam in children and adults (4-65 years) as an adjuvant treatment for focal-onset seizures. It was conducted among 114 patients undergoing treatment with up to three ASMs. The primary efficacy analysis was based on the proportion of patients who achieved a reduction of ≥ 50% in the mean number of focal seizures per week, over a 16-week treatment period. The patients were randomized to receive placebo or levetiracetam, titrated every two weeks from 20 mg/kg/day or 1,000 mg/day up to 60 mg/kg/day or 3,000 mg/day. Results: Levetiracetam was significantly superior to placebo (p = 0.0031); 38.7% of the participants in the levetiracetam group and 14.3% in the control group shows reductions in focal seizures. Levetiracetam was seen to have a favorable safety profile and an adverse event rate similar to that of placebo. Conclusion: Corroborating the results in the literature, levetiracetam was shown to be effective and safe for children and adults with refractory focal-onset epilepsy.